4

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form	1449A/P	TÓ	Com	plete if Known	
PE	STATE	MENT	N DISCLOSURE BY APPLICANT sheets as necessary)	Application Number	09/445,865	
١ ،	L - E1	ao many (mode do nococa,,,	Filing Date	February 11, 2000	
YARO	3			First Named Inventor	Philip John Burke	
, , , , , , , , , , , , , , , , , , ,	T& TRADERE			Group Art Unit	1643	
PATEU	TRADE			Examiner Name		
Sheet	1 1	of	9	Attorney Docket Number	ERD 100	

				U.S. PATENT DOCUMEN	NTS	
xaminer Initials*	Cite No.1	US Patent Docur	ment	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ		Code ² known)			
		4,440,859		Rutter,-et-al,-	04-03-1984	
COMPANY TO A STATE OF THE STATE	**************	4,530,901		Weissmann	07-23-1985	ATT AND
A THE THE PARTY OF		4,582,800	COLUMN TO SERVE	CIOWI	04-15-1986	
AGNORICE7*		4,67,7,063		Mark; et al mission supplies commence and supplies and su	06-30-1987	was a second
		4,678,751		Goeddelaterate the contract the second management of the second	07-07-1987	
		4,704,362	美国大教教学		1.1-03-1987	
الدينة رود المن الا	, and tooks	4,710;463	a	Murray Murray	12-01-1987	PROCESS
~		4.757.006	-		07-12-1988	
20000000		4;766;075=====	Market C.		08-23-1988	
るとのはのないので	SHEW THE	4,810,648	#1.12.12#m	Stalker	03:07:1989	and the control of th
	ļ					
	 					
			-			
			<u> </u>			
	 -				 	
			 			
	1					

						<u></u>	
Examine Signature	(an Rome	xl	Date Considered	41	2/	01	
Oignature	1 HOUSE						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please	type a	plus	sign (+) inside	this	box →

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collect Substitute for form 1449A/PTO	ction of information unless it contains a valid OMB of Complete if Known	control number
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/445,865
(use as many sneets as necessary)	Filing Date	February 11, 2000
O MAY O L 2000 ES (use as many sneets as necessary)	First Named Inventor	Philip John Burke
MAN O	Group Art Unit	1643
	Examiner Name	
She VENTE 9	Attorney Docket Number	ERD 100

				F	OREIGN PATENT DOCUMENT	S		
Examiner Cite Initials* No.1		Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Office.3		Kind Code ⁵ (if known)				
THE PERSON NAMED IN	ATMINISTRA	EP	0.251.744	A2:	Delta-Biotechnology-Ltd:	01-07-1988	STATE OF THE PARTY	ļ
CHICKSON,			0.258:067:	A2smmemir	Delta:Biotechnology:Ltd:	03:02:4988		
the second	अन्तर्भाष्ट्र व				Bristol Myers Co:			ـــــــ
On the same		A STATE OF THE PARTY OF THE PAR			The: Wellcome, Foundation, Ltd.			
	- The second	متنسO.W	88/07/37/8	Aslamenamica	©ancer-Research-Gampaign	1.0-06-1.988		
ಇತ್		WO _{wu}	89/10140	A1	Cancer Research Campaign Technology Ltd.			
TECTOR!	MARKED TO	WO	90/01063	ANEXTRACE	Delta Biotechnology Ltd.	02-08-1990	ALMA CIPARTES	
	-	wo	91/09867	A1	Imperial Cancer Research Technology Ltd.	07-11-1991	and the state of t	
	-10000	wo	91/11201	A1	Imperial_Cancer_Research Technology Ltd.	08-07-1991	TO STANDARD AND AND AND AND AND AND AND AND AND AN	
GN		wo	93/08288	Α1	Cancer Research Campaign Technology Ltd.	04-29-1993		
No.		M _©	93/43805	Adenes		07-22-1993		
** Capper	ಆಗುವರ್ಧನ	WO ×	93/13806	A.1	Bagshawe	07-22-1993		
GW			95/12678	A1	Cancer Research Campaign Technology Ltd.	05-11-1995]
GN		wo	97/07097	A1	Auckland Division Cancer Society of New Zealand	02-27-1997		
GN	1	wo	97/24143	A1	AEPACT, Ltd.	07-10-1997		
A CONTROL OF	- Sectional Co.	WO:	97/20580	Avanacia	AEPACT? Ltd:	06-12-1997		
harmen	r abratana	WO	97/24143	A.l.	AEPACT, Ltd.	07-10-1997		
GN		wo	98/22577	A1	Masucci	05-28-1998		
	-	WO***	98/24478	A2	AERACT, Ltd	06-11-1998	- THE STATE OF THE	

				,	
Examine Signature	(surposite	Date Considered	12	/ 0	/
o.gatoro					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

			PTC)/SB/08A	(10-9
	Approved for u	use through	10/31/99.	OMB 065	1-003
Patent and T	rademark Office:	U.S. DEPA	ARTMENT (OF COMM	IERC

Substitute for form 1449A/PTO	Co	mplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/445,865
(use as many sheets as necessary)	Filing Date	February 11, 2000
	First Named Inventor	Philip John Burke
MAY O A 7000 EXTUSE AS THAITY SHEETS AS THE CESSARY)	Group Art Unit	1643
` _3	Examiner Name	
		ERD 100

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	عفة تعاديد	ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)I. Purification and properties of a nitroreductase enzyme from Escherichia colleta potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 1992 44(12):2289-95.	
in contractor	(Carried Maria)	BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," Science 240(4855):1041-43 (1988).	
		BIRD, et al., "Single-chain antigen-binding proteins," Science 242(4877):423-26 (1988).	
Parket State State		BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," Science 27.4(5286):373-76s(4)996)	
*CONTRACTOR OF THE PARTY OF THE		BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB*1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," Biochem. Pharmacol. 41(6-7):867-75 (1991).	
***		BRADL, et al., "Malignant melanoma in transgenic mice," Proc. Natl. Acad. Sci. U. S. A. 88(1):164-68 (1991).	
	1.55 MBT	BRAWER, "Prostate specific antigen Areview," Acta. Oncol. 30(2):161-68 (1991).	
ROTINGES:	SASA	CHEN, et al. "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177," Biochem. J. 284 (Ppt 3):855-60 (1992).	
THEFT	PINASE	CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," J. Biol. Chem. 272(3):1437-39 (1997).	
1000	श्वासकार	CLARK, et al., "Role of the Bp35 cell surface polypentide in human B-cell activation," Proc. Natl. Acad. Sci. U. S. A. 82(6):1766-70 (1985).	

			 		1_		 	
Examiner's Signature	auko	W. XD	 Date Considered	41	2	/o	 _	
	 <i>y</i> -	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

•	-	۰

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 09/445,865 INFORMATION DISCLOSURE COSTATEMENT BY APPLICANT use as many sheets as necessary) February 11, 2000 Filing Date First Named Inventor Philip John Burke Group Art Unit 1643 **Examiner Name** ERD 100 Attorney Docket Number 9 of

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T'
	-	CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between flucuronidase activity and tumour sensitivity," Nature 210(38):866-67 (1966).	
Parts set 59	MATERIA	CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (GEA) and vine a alkaloids; a Cancer Immunol. Immunother. 24(2):127-32 (1987).	
	TE OWNER	CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody;" **CancersImmunother:::24(2):138-43-(1987).	
er en	CONTRACTOR OF THE PARTY OF THE	CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," Cancer Immunol. Immunother. 24(2):133-37 (1987).	
		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc. Natl. Acad. Sci. U. S.</i> A. 89(13):6094-98 (1992).	
102035	GENTALS	A. 89(13):6094-98 (1992). COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene," Science 230(4730):1132-39 (1985).	
Thursday.	SECTION SECTION	CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," Science 256(5063):1550-52 (1992).	
KUPHERITETE	CONVER	CURIEL "Adenovirus facilitation of molecular conjugate mediated gene transfer," Prog. Med. Virol. 40:1-18 (1993).	
GN		DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," Gene Ther. 4(2):93-100 (1997).	
(h)		FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," <i>Biochem. Pharmacol.</i> 44(4):631-35 (1992).	

			_		
Examiner's	 Date Considered	1//	\sim 1	\sim /	
		~ <i>\ </i>		/) /	
Signature			~1	V 4	
o ignature		$\overline{}$			
		•	,		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+	+) inside this box →
----------------------------	----------------------

PTO/SB/08A	(10-96
Approved for use through 10/31/99. OMB 0651	i-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMM	FRCF

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 09/445,865 TATEMENT BY APPLICANT use as many sheets as necessary) Filing Date February 11, 2000 First Named Inventor Philip John Burke **Group Art Unit** 1643 **Examiner Name** of 9 Attorney Docket Number ERD 100

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Ī
	el en marche	FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," Biochem. Pharmacol. 44(1):25-31 (1992).	
Contract of the	Carreston.	FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," Biochem. Pharmacol. 44(9):1739-43 (1992).	
ORCHES	was b	GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl. Acad. Sci. U. S. A. 85(20):771923 (1988):	
GN		GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene," Cancer Gene Ther. 4(4):229-38 (1997).	
·em:63	uzealna	HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a GEA-producing-humanzcolon-tumour-xenograft," Eur. J. Cancer Clin. Oncol. 21(12):1515-22 (1985).	
- DESCRIPTION IS	9F 3G1	HELLSTRÖM, et al. "Monoclonal mouse antibodies raised against human lung carcinoma," Cancer Res. 46(8):3917- 23"(1986).	
×2023		HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press).	
CILIDATE S	elen,	HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coll, "Proc. Natl. Acad. Sci. U. S. A. 85(16):5879-83 (1988).	
فأخفت بدير هدمر	intica :	JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," Nucleic Acids Res (14):3799-804 (1991)	
estar :	Take.	JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," J. Biol. Chem. 269(20):14502-08 (1994).	

Examiner's	(- Roy Ch)	Date Considered 4/2/2/	
Signature	- POWITY YUUW		
	9		_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box \rightarrow	+	ı
	1 !	Ì

of

9

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ERD 100

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

Application Number

O9/445,865

Filing Date
First Named Inventor
Group Art Unit
Examiner Name

Attorney Docket Number

Examiner's Cite Initials. Other Initials of the author (in CAPITAL LITERATURE DOCUMENTS) Itiem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NOO2) corresponding to a second memberof-the-NAC(P)PI, quinone oxido/case gane-trainity=Extensive polymorphism at the NOO2 gene locus on chromosome 6," Biochemistry, 29(7):1899-906 (1990). KHAN & ROSS, Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships, Chem. Biol. Interact. 1(1):27-47 (1969). KNOX, et al., "The bioactivation of 5-faziridin-1-yi)-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase; Biochem. Pharmacol. 44(12):2297-301 (1992). KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a effortivital vector," Cell Struct. Funct. 16(6):503-10 (1991). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," Biochem. Pharmacol. 6:53-52 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," J. Biol. Chem. 237:2981-874(1962).				
Include name of the author (in CAPITAL LETTERS), lide of the article when appropriate), tille of the include when appropriate), tille of the include when appropriate), tille of the include when appropriate), and the published letter the color intermediate and deduced amino acid sequence of a human cDNA (NOO2) corresponding to a second member of the NAO(P) Highinone oxidoreductase general family extensive polymorphism at the NOO2 gene locus on chromosome 6, "Biochemistry, 29(7):1899-906 (1990). KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," Chem. Biol. Interact." (11):27-47 (1969) KNOX, et al., "The bioactivation of 5-faziridin-1-yll-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escherichia coli nitroreductase and Walker D "diaphorase," Biochem. Pharmacol. 44(12):2297-301 (1992). KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," Cell Struct. Funct. 16(6):503-10 (1991). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biochem. Pharmacol. 6:93:54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the evidation of some dihydropyridines by polycyclic aromatic hydrocarbons," Biochem. Pharmacol. 6:93:54 (1961).		T	OTHER ART - NON PATENT LITERATURE DOCUMENTS	
JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the MAD (P)H quinone oxidoreductase gene family Extensive polymorphism at the NQO2 gene locus on chromosome 6," Biochemistry, 29(7):1899-906 (1990). KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," Chem. Biol. Interact. 1(11):27-47 (1969) KNOX, et al., "The bioactivation of 5-(aziridin-1-y))-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escherichia coli nitroreductase and Walker D1 diaphorase." Biochem. Pharmacol. 44(12):2297-301 (1992). KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrug in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," Cell Struct. Funct. 16(6):503-10 (1991). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Comm. 4:208-13.(1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic flydrocarbons," Biochem. Pharmacol. 6:53:54 (1961). LIAO, et al., "Purification and properties of a flavorrotein catalyzing the oxidation of softend ribacle in the college."			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s)	T²
KHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships," Chem. Biol. Interact. 1(1):27-47 (1969) KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escherichia coll nitroreductase and Walker DT diaphorases," Biochem. Pharmacol. 44(12):2297-301 (1992). KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," Cell Struct. Funct. 16(6):503-10 (1991). LEDLEM: Nonviral gene therapy: the promise of genestas pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 (1995). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Gomm. 41:008-13 (1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic mydrocarbons," Biochem. Pharmacol. 6:53-54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the exidation of solution of solution in the production of solution of solutio	Managha .	a arielandan	JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAO(P)H:quinone oxidoreductase gene family Extensive polymorphism at the NQO2 gene locus on chromosome 6," Biochemistry, 29(7):1899-906 (1990)	
KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993). KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy" (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," Cell Struct. Funct. 16(6):503-10 (1991). LEDLEM:*Nonviral gene therapy: the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 (1995). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biochem. Pharmacol. 6:53-54 (1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons," Biochem. Pharmacol. 6:53-54 (1961).		e e e e e e e e e e e e e e e e e e e	IKHAN & ROSS, "Tumour-growth inhibitory nitrophenylaziridines and related compounds; expecture activities	
KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," Cell Struct. Funct. 16(6):503-10 (1991). LEDLEX: "Nonviral gene therapy the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 (1995). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Comm. 4:208-13 (1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic flydrocarbons," Biochem. Pharmacol. 6:53-54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of sorted sibalytics of reduced sibalytics o	TATAL		Con introleductase and walker Di-diaphorase Blochem, Pharmacol. 44(12):2297-301 (1992).	
KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector, "Cell Struct. Funct. 16(6):503-10 (1991). LEDLEY, "Nonviral gene therapy: the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 (1995). LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Comm. 4:208-13(1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic mydrocarbons," Biochem. Pharmacol. 6:53-54 (1961).	GN	Ė	KNOX, et al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993).	
LEDLEY, "Nonviral gene" therapy the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Comm. 4:208-13 (1961). LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic mydrocarbons," Biochem. Pharmacol. 6:53:54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced should be all."		ware.	KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995).	
LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem. and Biophys. Res. Comm. 4:208.13.(1961) LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic riydrocarbons," Biochem. Pharmacol. 6:53-54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced should be all."	CARREST.	S.MAR.S.	KURIYAMA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector," <i>Cell Struct. Funct.</i> 16(6):503-10 (1991).	
LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic liydrocarbons," Biochem. Pharmacol. 6:53-54 (1961). LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced sibaryleics in the content of th	F.S.T.	Esternia.	LEDLEM: Nonviral gene therapy: the promise of genesias pharmaceutical products," Hum. Gene Ther. 6(9):1129-44 (1995).	-
LIAO, et al., "Purification and properties of a flavoprotein catalyzing the evidation of reduced site and properties of a flavoprotein catalyzing the evidation of reduced site and properties."	-		LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide," Biochem and Biophys Res Comm 4:208:13:1961	
LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," J. Biol. Chem. 237:2981-87 (1962)	2000	HERCH	LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic mydrocarbons," Biochem. Pharmacol. 6:53-54 (1961).	
	· MOSTER STATE	eroprotec	LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide," J. Biol. Chem. 237:2981-87 (4962)	

Examiner's Signature Date Considered 4/2/01

*EXAMINER: Initial if reference considered, whether or not election is in section in its section.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

Please type a plus sign (+) inside this box \rightarrow	+

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 09/445,865 (use as many sheets as necessary) Filing Date February 11, 2000 First Named Inventor Philip John Burke **Group Art Unit** 1643 **Examiner Name** 9 of Attorney Docket Number ERD 100

	T 400	OTHER ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T
muais	INO.	item (000k, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s)	Ι΄
	┼	publisher, city and/or country where published	
	1	LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," Biochem.	┢╌
-		Biophys. Res. Commun. 161(3):1151-941089	
		MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An	L
-	ALCOHOL:	improved method for liposome targeting	
		MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction	
SUCCESSION OF STREET	STATE OF THE PARTY	with a filtroreductase enzyme, J. Med. Chem. 37(21):3452-58 (1994).	
Z**W\$		MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," Gene Ther. 2(9):660-68 (1995).	
2.75.244	220.62.2	MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," Gene Ther. 2(9):660-68 (1995).	
		MILLER & VILE, "Targeted vectors for gene therapy," FASEB J. 9(2):190-99 (1995)	
ate	SCORT'S		
	26195X5	MORRISON, et al. "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region	
per excitation.		domains," Proc. Natl. Acad. Sci. U. S. A. 81(21):6851-55 (1984).	
		NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR 3) in	
PRODUCTION OF THE PROPERTY OF	ALM MARINE	NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice," Cancer Res. 52(3) 646-53 (1992).	
		NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," Nature 312(5995):604-08	
pc , 4588 14 GE	N. 4045-338	(1984). Nature 312(5995):604-08	
	ensure.	O⊱SULLIVAN, et als. Comparison of two methods of preparing enzyme-antibody conjugates: application of these	
M'San Var		conjugates for enzyme immunoassay," Anal. Biochem. 100(1):100-08 (1979).	
		RIEGMAN, et al. "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene," Biochem. Biophys. Res. Commun. 159(1):95-102 (1989).	
THE PROPERTY OF	3615-E21797	Biochem. Biophys. Res. Commun. 159(1):95-102 (1989).	

Examiner's Signature Date Considered 1/2/0/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	ĺ	-

PTO/SB/08A (10-96
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB or

8	Substitute for form 1449A/PTO		The Court Court Court of Harrises
			Complete if Known
PE	INFORMATION DISC STATEMENT BY AP as many sheets as no	PLICANT Application Number	09/445,865
b	as many sheets as no	ecessary)	
'ه . ``	· S	Filing Date	February 11, 2000
MAN	<i>₹</i>	First Named Inventor	Philip John Burke
χ,		Group Art Unit	1643
Sho ATEN		Examiner Name	
Sileer	8 of	9 Attorney Docket Number	ERD 100
Well constant of	SAIKI, et al., "Primer-direct 239(4839):487-91 (1988	magazine, journal, serial, symposium, catalog, etc.), de publisher, city and/or country where puted enzymatic amplification of DNA with a tr.).	nermostable DNA polymerase," Science
The second of the second	SHARMA at al. "Incating	Jof the complete gene for carcinoembryonic sepecific expression, <i>Mol. Cell. Biol.</i> 10(6):27 tion and clearance of an anti-CEA carboxypep <i>Cancer</i> , 61(5):659-62 (1990).	antigen: analysis of its promoter indicates a 738-48 (1990). otidase G2 conjugate in blood after localisation
GW		drug delivery reviews: enzyme prodrug therapy	y," Adv. Drug Del. Rev. 22:269-88 (1996).
	SKERRA, et al., "Assembly	of a functional immunoglobulin Fv fragment	in Escherichia coli," Science

A DOWN BOOM SCH	ЖНІS 206(9	SON:&©ONNORS 985):689-91 (1965).	'Curerofamiceabear	ing advanced plasma	e cell tumours w	ith anilin	e mus	tard," i	Nature	 +-
Examiner's Signature	Con	uroni	ils		Date Considered	4	1/2	61		<u></u>

TROWELL, "The cytocidal action of mitotic poisons on lymphocytes in vitro," Biochemical Pharmacology 5:53-63 (4:960):

WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," *Proc. Natl. Acad. Sci. U. S. A.* 87(9):3410-14 (1990).

WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature 341(6242):544-46 (1989).

240(4855):1038-41 (1988):

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	+

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0851-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known **INFORMATION DISCLOSURE** Application Number 09/445.865 STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date February 11, 2000 First Named Inventor Philip John Burke **Group Art Unit** 1643 **Examiner Name** of 9 Attorney Docket Number **ERD 100**

F	1 00	OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where a publisher city and/or country where city and	T
·		WINTER & MILSTEIN, "Man-made antibodies," Nature 349(6307):293-99 (1991).	
- 5 10 10		WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside	
		втортув. 347(2):221-28 (1997).	
		ZOLA, "Monoclonal Antibodies Amanual of techniques," (CRC Press, 1988).	
			_
ĺ			
			-
	İ		
			+-
			┼
L			

Examiner's	Date Considered 1	<i></i>
Signature My Mills	Date Considered 4/2	101
		/ <u> </u>
*EYAMINED: Initial it as a	· . ,	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

1 Unique citation designation number 2 See attached Kinda of U.S. Debugge 3.7 miles and 1.5 miles are also attached Kinda of U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles are also attached by the U.S. Debugge 3.7 miles a

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.